Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.64 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4003133 | 0.85 | HRH4 (0.72) | HRH4NUDT1 | |
| SCHEMBL24851757 | 0.80 | ALDH1A1 (0.49) | NUDT1GPR119ALDH1A1NPC1MAPT | |
| SCHEMBL3196914 | 0.78 | CKS1B (0.49) | HRH4NUDT1GPR119MAP4K4 | |
| SCHEMBL7774440 | 0.78 | HRH4 (0.55) | HRH4GPR119ALDH1A1MAPTMAP4K4 | |
| SCHEMBL3996342 | 0.78 | HRH4 (0.97) | HRH4NUDT1 | |
| SCHEMBL30260169 | 0.77 | HRH4 (0.44) | HRH4GPR119ALDH1A1NPC1MAPT | |
| SCHEMBL23684360 | 0.77 | HRH4 (0.44) | HRH4GPR119ALDH1A1NPC1MAPT | |
| SCHEMBL23684695 | 0.77 | PRKD1 (0.48) | HRH4ALDH1A1 | |
| Acetic Acid SCHEMBL604873 | 0.77 | HRH4 (0.69) | HRH4NUDT1 | |
| SCHEMBL3789071 | 0.77 | ALDH1A1 (0.54) | GPR119ALDH1A1NPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | claimed |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | HRH4 1/4885NUDT1 76/4885GPR119 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.